Elbit Imaging Ltd. Announces That Gamida Cell’s Phase 3 Study of NiCord for Blood Cancers is Now Enrolling
13 December 2016 - 4:20AM
Elbit Imaging Ltd. (TASE:EMITF)
(NASDAQ:EMITF) ("
Elbit" or the
"
Company") announced today that it was
informed by Gamida Cell Ltd. ("
Gamida Cell"), an
indirect associate of the Company, that Gamida Cell has been
cleared by the U.S. Food and Drug Administration to begin enrolling
for the Phase 3, international, multicenter trial of Gamida Cell's
NiCord® for patients with high risk hematological malignancies
(blood cancers) (the "
Trial"). In addition, Gamida
Cell has informed the Company that clearance to begin enrolling for
the NiCord study has also been received for an additional European
territory.
The Trial is planned to be a
randomized-controlled study comparing transplantation of NiCord to
that of un-manipulated umbilical cord blood. A total of 120
patients will be enrolled at transplantation centers throughout the
US and Europe. Gamida Cell estimates that patient recruitment will
take approximately two years to complete. The primary endpoint of
the study is to examine the time from transplant to engraftment of
neutrophils.
As of today, the development of NiCord remains
at the clinical stage of development.
Gamida Cell develops cellular and immune
therapies for the treatment of cancer and orphan genetic diseases.
Gamida Cell's lead pipeline products are in clinical development as
alternative therapeutic treatments for many patients indicated for
bone marrow transplant, but who cannot find the necessary fully
matched donor. These include NiCord for blood cancers and
CordIn for sickle cell disease and thalassemia.
The Company holds approximately 89.9% of the
share capital of Elbit Medical Technologies Ltd. (TASE:EMTC-M)
(85.6% on a fully diluted basis) which, in turn, holds
approximately 25% of the share capital in Gamida (22.5% on a fully
diluted basis).
About Elbit Imaging Ltd.
Elbit Imaging Ltd. operates in the following
principal fields of business: (i) Commercial centers - initiation,
construction, and sale of commercial centers and other mixed-use
property projects, predominantly in the retail sector, located in
Central and Eastern Europe. In certain circumstances and depending
on market conditions, the Group operates and manages commercial
centers prior to their sale. (ii) Hotel - operation and
management of the Radisson hotel complex in Bucharest, Romania.
(iii) Medical industries and devices - (a) research and
development, production and marketing of magnetic resonance imaging
guided focused ultrasound treatment equipment, and (b) development
of stem cell population expansion technologies and stem cell
therapy products for transplantation and regenerative medicine.
(iv) Plots in India - plots designated for sale initially
designated to residential projects.
Any forward-looking statements in our releases
include statements regarding the intent, belief or current
expectations of Elbit Imaging Ltd. and our management about our
business, financial condition, results of operations, and its
relationship with its employees and the condition of our
properties. Words such as “believe,” “expect,” “intend,” “estimate”
and similar expressions are intended to identify forward-looking
statements but are not the exclusive means of identifying such
statements. Actual results may differ materially from those
projected, expressed or implied in the forward-looking statements
as a result of various factors including, without limitation, a
change in market conditions, a decision to deploy the cash for
other business opportunities and the factors set forth in our
filings with the Securities and Exchange Commission including,
without limitation, Item 3.D of our annual report on Form 20-F for
the fiscal year ended December 31, 2015, under the caption “Risk
Factors.” Any forward-looking statements contained in our releases
speak only as of the date of such release, and we caution existing
and prospective investors not to place undue reliance on such
statements. Such forward-looking statements do not purport to be
predictions of future events or circumstances, and therefore, there
can be no assurance that any forward-looking statement contained in
our releases will prove to be accurate. We undertake no obligation
to update or revise any forward-looking statements.
For Further Information:
Company Contact
Ron Hadassi
Chairman of the Board of Directors
Tel: +972-3-608-6048
Fax: +972-3-608-6050
ron@elbitimaging.com
Elbit Imaging (CE) (USOTC:EMITF)
Historical Stock Chart
From Apr 2024 to May 2024
Elbit Imaging (CE) (USOTC:EMITF)
Historical Stock Chart
From May 2023 to May 2024